Towa Pharmaceutical Co., Ltd.

As of March 31, 2026, Towa Pharmaceutical Co., Ltd. carries a market capitalization of 197.16B, placing it among publicly traded companies globally. Its enterprise value stands at 378.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Towa Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 11, 2026.

As of March 31, 2026, Towa Pharmaceutical Co., Ltd. has 49.23M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Towa Pharmaceutical Co., Ltd. maintains a current ratio of 2.76, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Towa Pharmaceutical Co., Ltd.'s stock has gained approximately 25.52% over the past 52 weeks. The 50-day moving average sits at 3,685.40, while the 200-day moving average is 3,872.83.

As of March 31, 2026, Towa Pharmaceutical Co., Ltd. holds 45.31B in cash and equivalents against 226.74B in total debt, resulting in a net debt position of 166.90B. Total book value stands at 178.10B, with working capital of 170.48B providing operational flexibility.

Towa Pharmaceutical Co., Ltd.'s most recent stock split took place on March 27, 2019 with a 1:3 split ratio.